Most Recent Articles by Warren Ross
Call it the law of unintended consequences or the perfect storm or a bad hair day or any other cliché you can think of, but as 2009 came to a close we once again faced a cluster of bad news for the pharma industry.
American consumers are used to warranties. If you buy a TV set and it stops working within a specified time, you can ask for a replacement or to have it fixed.
Mr. Ross, when you headed KPR Informedia, did you submit articles to medical journals that were ghostwritten?
Pharma and biotech companies are competing to have enough vaccine on hand for the next swine flu (H1N1) outbreak. They missed the one last winter and spring, and their response has uniformly been: We'll be ready next time.
What the FDA euphemistically calls "guidances" are usually received by industry with something less than cheers. Despite the name, the guidances are often perceived as directives to be ignored at your peril.
More Articles by Warren Ross
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- FCB Health's Rich Levy on HIV/AIDS Campaigns that Fight Stigma
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy